Mednet Logo

Is 80 Gy/40 Fx + ADT the new standard of care for definitive radiation of high risk prostate cancer?

GETUG-AFU 18 has shown a survival benefit over 70 Gy. There is much pressure to hypofractionate, but this is the first study showing a survival benefit with dose escalation with conventional fractionation.
2 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on · Updated on

For those who want a more thorough answer, enjoy. If you want you can skip to the end for the summary:

For well over a decade, we are taught that dose escalation improves biochemical control but not overall survival, while ADT improves both. Do the results of GETUG AFU-18 change this? Let's take a l...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Northside Hospital Cancer Institute Radiation Oncology – Atlanta
Answered on · Updated on

@Dr. First Last,

All data points to dose (i.e., BED) mattering for higher risk CaP. That said, for amenable patients, I dose-escalate via brachy-boost following EBRT in my practice as per ASCENDE. For non-brachy candidates being treated with definitive beam, I had recently switched from standard fx ...

Join for free or sign in to see the full answer